Amoy Diagnostics (SHE:300685) secured regulatory approval from China's medical products administrator for the expanded use of its cancer gene detection kit.
The Human 10-Gene Mutation detection kit can now detect EGFR exon 20 insertion mutations in plasma samples from non-small cell lung cancer patients, according to a Monday filing with the Shenzhen bourse.
Shares of the diagnostics company closed 1% higher Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.